LPTX241115P5000
- 1.00
- 0.000.00%
Leap Therapeutics Newsroom
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Leap Therapeutics Price Target Maintained With a $5.50/Share by HC Wainwright & Co.
Leap Therapeutics Analyst Ratings
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Maintained Buy Rating for Leap Therapeutics Amid Promising Clinical and Financial Outlook
Leap Therapeutics: Runway To Fund Operating, Capital Spending Into 2Q 2026 >LPTX
Leap Therapeutics Analyst Ratings
Rodman & Renshaw Initiates Coverage On Leap Therapeutics With Buy Rating, Announces Price Target of $8
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
Leap Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $5.5
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
Leap Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $7 Price Target
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
Maintaining Buy Rating on Leap Therapeutics: Promising DKN-01 Trials and Undervalued Market Potential
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Leap Therapeutics (LPTX)
Outperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial Outcomes